Mogens K. Boisen - Concepedia

Author

Mogens K. Boisen

Also Known As

Boisen, Mogens, M. Boisen, M.K. Boisen, Mogens Boisen, Mogens K. Boisen, Mogens K. Boisen (645207), Mogens Karsboel Boisen, Mogens Karsbol Boisen, Mogens Karsbøl Boisen

Publications

620

Citations

H-Index

Concepts

All Affiliations

University of Copenhagen Gentofte Hospital Danish Cancer Society Herlev Hospital Rigshospitalet

About

Mogens K. Boisen is an author at University of Copenhagen specializing in colorectal cancer, medicine, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	1	1	87
2	Pathology	1	1	87
3	Cancer Therapeutics	1	1	87
4	Colorectal Cancer	1	1	87
5	Oncology	1	1	87

Mogens K. Boisen

Publications

528

Citations

H-Index

Page 1

	Year	Citations
Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer Mogens K. Boisen, Julia S. Johansen, Christian Dehlendorff, Annals of Oncology Primary Tumor LocationOncologyGastrointestinal OncologyBevacizumab EffectivenessPathology	2013	87
Tissue MicroRNA profiles as diagnostic and prognostic biomarkers in patients with resectable pancreatic ductal adenocarcinoma and periampullary cancers Dan Calatayud, Christian Dehlendorff, Mogens K. Boisen, Biomarker Research	2017	67
COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis Rikke B. Holmstroem, Ole Haagen Nielsen, Søren Jacobsen, Journal for ImmunoTherapy of Cancer	2022	62
Postoperative serum CA19-9, YKL-40, CRP and IL-6 in combination with CEA as prognostic markers for recurrence and survival in colorectal cancer Kethe Hermunen, Leena‐Maija Soveri, Mogens K. Boisen, Acta Oncologica	2020	50
Tissue MicroRNAs as Predictors of Outcome in Patients with Metastatic Colorectal Cancer Treated with First Line Capecitabine and Oxaliplatin with or without Bevacizumab Mogens K. Boisen, Christian Dehlendorff, Dorte Linnemann, PLoS ONE	2014	44
MicroRNA Expression in Formalin-fixed Paraffin-embedded Cancer Tissue: Identifying Reference MicroRNAs and Variability Mogens K. Boisen, Christian Dehlendorff, Dorte Linnemann, BMC Cancer	2015	32
Prognostic value of blood-based fibrosis biomarkers in patients with metastatic colorectal cancer receiving chemotherapy and bevacizumab Neel I. Nissen, S.N. Kehlet, Mogens K. Boisen, Scientific Reports	2021	31
Serum IL6 as a Prognostic Biomarker and IL6R as a Therapeutic Target in Biliary Tract Cancers Dan Høgdall, Colm J. O’Rourke, Christian Dehlendorff, Clinical Cancer Research	2020	29
Whole blood microRNAs capture systemic reprogramming and have diagnostic potential in patients with biliary tract cancer Dan Høgdall, Colm J. O’Rourke, Finn Ole Larsen, Journal of Hepatology	2022	23
The Prognostic Value of Plasma YKL-40 in Patients With Chemotherapy-Resistant Ovarian Cancer Treated With Bevacizumab Mogens K. Boisen, Christine Vestergaard Madsen, Christian Dehlendorff, International Journal of Gynecological Cancer	2016	21

Page 1